| Univariate | Multivariate | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Local failure | ||||
 Gender | 1.26 (0.57–2.77) | 0.573 |  |  |
 Age | 1 (0.97–1.04) | 0.912 |  |  |
 Histology | 1.08 (0.83–1.4) | 0.576 |  |  |
 Residual tumor | 1.22 (0.42–3.58) | 0.712 | 1.55 (0.47–5.1) | 0.475 |
 GPA score | 0.66 (0.36–1.21) | 0.18 | 0.82 (0.42–1.59) | 0.552 |
 PTVres > 15 cm3 | 3.42 (1.54–7.62) | 0.003 | 3.2 (1.37–7.48) | 0.007 |
 BED < 40 Gy | 6.33 (2.5–15.9) | < 0.001 | 5.71 (2.05–15.9) | 0.001 |
 MRI FU at 3 months | 0.97 (0.43–2.16) | 0.936 | 0.96 (0.39–2.37) | 0.926 |
 ≥ 1 MRI per 180 days | 1.4 (0.63–3.14) | 0.412 |  |  |
Distant brain failure | ||||
 Gender | 1.18 (0.62–2.24) | 0.61 |  |  |
 Age | 1.02 (0.99–1.05) | 0.201 |  |  |
 Histology | 1.07 (0.87–1.32) | 0.535 |  |  |
 Residual tumor | 1.26 (0.58–2.73) | 0.559 | 1.52 (0.67–3.45) | 0.322 |
 GPA score | 0.42 (0.26–0.67) | < 0.001 | 0.46 (0.28–0.74) | 0.001 |
 PTVres > 15 cm3 | 3.7 (1.97–6.97) | < 0.001 | 3.18 (1.34–6.16) | 0.001 |
 BED < 40 Gy | 2.1 (0.78–5.68) | 0.143 | 1.31 (0.45–3.8) | 0.623 |
 MRI FU at 3 months | 0.97 (0.52–1.81) | 0.912 | 1.19 (0.59–2.38) | 0.628 |
 ≥ 1 MRI per 180 days | 1.44 (0.76–2.71) | 0.262 |  |  |
Overall survival | ||||
 Gender | 1.57 (0.86–2.88) | 0.141 |  |  |
 Age | 1.01 (0.98–1.04) | 0.637 |  |  |
 Histology | 1.65 (0.96–1.41) | 0.115 |  |  |
 Residual tumor | 2.91 (1.58–5.38) | 0.001 | 2.4 (1.29–5.64) | 0.008 |
 GPA score | 0.39 (0.24–0.62) | < 0.001 | 0.42 (0.26–0.69) | 0.001 |
 PTVres > 15 cm3 | 2.67 (1.47–4.85) | 0.001 | 2.29 (1.22–4.31) | 0.01 |
 BED < 40 Gy | 3.38 (1.31–8.7) | 0.012 | 2.28 (0.82–6.33) | 0.113 |
 MRI FU at 3 months | 0.8 (0.44–1.45) | 0.461 | 1 (0.52–1.92) | 0.993 |
 ≥ 1 MRI per 180 days | 1.5 (0.83–2.72) | 0.183 |  |  |